New ALS Classification Reveals That Motor Neuron Type, Not Onset Site, Drives Survival

Amyotrophic lateral sclerosis has always been a disease of contradictions. Two patients of the same age, diagnosed on the same day, with symptoms that began in the same part of the body, can follow radically different trajectories: one may lose the ability to speak and breathe within a year, while the other remains ambulatory for a decade. For decades, neurologists have tried to capture this heterogeneity with classification schemes, from the crude bulbar-versus-spinal dichotomy to elaborate composite phenotypes. Now, a large population-based study from north-west Italy has done something more revealing than proposing yet another taxonomy: it has taken a new three-axis classification apart, dimension by dimension, to determine what each component actually contributes to prognosis. The answer overturns a long-standing assumption about what the site of symptom onset means for survival.

The study, published in the Journal of Neurology, drew on the PARALS registry, a prospective, population-based register of every incident case of ALS in the Piedmont and Aosta Valley regions between 2000 and 2022. From 2,808 patients with non-cognitive onset, the researchers assembled an analytic cohort of 2,738 individuals, of whom 2,561, or 93.5 percent, had reached the composite endpoint of death or tracheostomy by the end of 2025. This near-complete ascertainment of outcomes is what gives the analysis its power: rather than a selected clinic population, it captures the full demographic and clinical spectrum of ALS as it actually occurs in a defined geographic area, with a median age at onset of 67.8 years.

The classification under scrutiny is the ALS-OPM 3.3 system, a three-axis framework that summarises each patient at first observation along three dimensions. The O axis records the anatomical region of symptom onset across eight categories, from head and bulbar onset through distal, proximal and mixed arm and leg presentations to trunk-respiratory onset. The P axis measures propagation time, the interval in months from first symptoms to involvement of a second, distant body region. The M axis captures the motor-neuron pattern: whether upper and lower motor neurons are affected in balance, as in the classical Charcot form of the disease, or whether one population predominates. The Italian team operationalised this axis as a three-level variable, M0 for balanced involvement, M1d for upper motor neuron predominance and M2d for lower motor neuron predominance, which together covered 99 percent of the non-PLS cohort.

The survival differences across the motor-neuron axis were stark and highly significant. Patients with the balanced M0 pattern, roughly two-thirds of the cohort, had the shortest median survival at 27.0 months from onset. Those with lower motor neuron predominance, M2d, which includes the scapulohumeral flail-arm and flail-leg variants, survived a median of 36.0 months. The upper motor neuron predominant group, M1d, fared best at 41.9 months. A multivariate log-rank test confirmed that these three populations are genuinely distinct, with all pairwise comparisons highly significant. In adjusted Cox models, both M1d and M2d carried independently protective hazard ratios relative to M0, at 0.59 and 0.83 respectively, effects that persisted regardless of how the other axes were handled.

Propagation time emerged as the single most powerful prognostic ingredient of the framework. Each additional month of delay before disease spread to a second region reduced the adjusted hazard by roughly 3.3 percent, so that a twelve-month difference in propagation time corresponded to an approximate hazard ratio of 0.66. Median survival climbed from 21.0 months in the fastest tertile of propagation to 43.1 months in the slowest. Onset anatomy alone, by contrast, discriminated only modestly, raising the C-index from chance levels to about 0.57, while adding propagation lifted discrimination to 0.68 and the motor-neuron pattern and demographics brought it to roughly 0.71. The authors recommend the linear specification of propagation capped at 60 months as the primary model, since a more flexible spline added no significant gain.

The decisive experiment concerned the arm-proximal onset category, the topographic signature of the flail-arm syndrome, long regarded as an indolent form of the disease. In the cohort, 95.7 percent of arm-proximal patients belonged to the lower motor neuron predominant M2d class, making this onset region a near-deterministic proxy for that motor-neuron pattern. When the researchers modelled survival without accounting for motor-neuron pattern, arm-proximal onset appeared protective, with a hazard ratio of 0.86 relative to distal arm onset. But once the M axis entered the model, the protective effect of arm-proximal onset vanished entirely, rising to a hazard ratio of 0.99 with a confidence interval spanning unity, while the M2d term retained its significant protective effect of 0.83. The favourable prognosis attributed to the anatomical site was, in fact, a property of the underlying motor-neuron biology that the anatomy happened to signal.

This decomposition is the intellectual heart of the paper. The authors report that ALS-OPM 3.3 did not materially improve prognostic discrimination over the established classical phenotype classification, with optimism-corrected C-indices of 0.703 versus 0.701, and it did not surpass clinical staging systems or El Escorial diagnostic certainty. Rather than treating this as a failure, the researchers interpret it as the central finding: the new framework does not predict better than existing taxonomies, but it reveals what those taxonomies were implicitly measuring all along. Classical composite labels such as flail-arm bundle together onset topography and motor-neuron pattern into a single descriptor; OPM disaggregates that signal into three separately interpretable components, of which propagation kinetics is the dominant contributor and motor-neuron pattern the operative biological variable.

The framework also proved complementary to, rather than redundant with, the tools already in clinical use. Combining OPM with King’s staging, the Milano-Torino staging system, or the more recent Fine’til 9 system significantly improved discrimination over OPM alone, and the motor-neuron hazard ratios remained stable across all three staging frameworks. Even among patients at identical King’s baseline stages, those with upper or lower motor neuron predominance transitioned more slowly to severe clinical milestones than the balanced M0 group, with median time to King’s stage 4 reaching 64.4 and 60.4 months respectively against 40.5 months for M0. El Escorial diagnostic certainty, which largely reflects baseline multifocality, also added independent prognostic information, and the combination of El Escorial with the OPM axes achieved the highest discrimination of any model tested, at a corrected C-index of 0.7128.

The study is not without caveats, which the authors confront directly. The cohort, though population-based, comes from a single Italian region, and external validation in other incident registries will be needed. The propagation axis depends partly on patients’ recollection of when symptoms spread, though concordance with prospective functional-rating data was high and a landmark analysis confirmed the robustness of the findings. The primary lateral sclerosis spectrum subgroup was analysed separately to avoid immortal-time bias, and sensitivity analyses showed that its inclusion or exclusion left the principal motor-neuron effects unchanged. The classification is also purely motor, and does not capture the cognitive and behavioural dimensions of the disease that independently influence prognosis.

The practical implications reach from the neurologist’s consulting room to the design of clinical trials. A patient presenting with arm-proximal onset can now be counselled that the relatively favourable trajectory reflects the lower motor neuron predominant pattern rather than the site of onset itself, a distinction that purely anatomical classifications obscure. In trials, balancing treatment arms on motor-neuron pattern rather than onset topography would remove a hidden source of prognostic imbalance that composite labels leave undetected. More broadly, the study offers a template for how the field should evaluate any proposed classification: not by asking whether it predicts better, but by asking what, exactly, it measures. In the case of ALS motor phenotypes, the answer is now clear: the motor neurons themselves, and the speed at which the disease escapes its point of origin, matter far more than the map coordinates of the first symptom.

Subject of Research: Prognostic decomposition of ALS motor phenotype classifications in a population-based cohort

Article Title: What do ALS motor phenotypes measure? A population-based decomposition of their prognostic dimensions

Article References: Calvo, A., Moglia, C., Callegaro, S., Canosa, A., Manera, U., Mora, G., Cabras, S., Palumbo, F., Matteoni, E., Maccabeo, A., Pellegrino, G., Minerva, E., Pascariu, D., D’Ovidio, F., Vasta, R., Mazzini, L., De Marchi, F., & Chiò, A. (2026). What do ALS motor phenotypes measure? A population-based decomposition of their prognostic dimensions. Journal of Neurology, 273(10), Article 604. https://doi.org/10.1007/s00415-026-14134-z

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14134-z

Keywords: amyotrophic lateral sclerosis, motor phenotype, prognosis, population-based registry, survival analysis, motor neurons, disease staging, OPM classification, flail-arm syndrome, disease propagation, Cox model, clinical trials